HNB
CRNX

Huntington National Bank’s Crinetics Pharmaceuticals CRNX Stock Holding History

Huntington National Bank’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.4K Sell
545
-28
-5% -$1.04K ﹤0.01% 1766
2026
Q1 		$20.8K Sell
573
-46
-7% -$2.06K ﹤0.01% 1635
2025
Q4 		$28.8K Buy
619
+24
+4% +$1.07K ﹤0.01% 1452
2025
Q3 		$24.8K Sell
595
-32
-5% -$1.02K ﹤0.01% 1521
2025
Q2 		$18K Buy
627
+78
+14% +$2.41K ﹤0.01% 1613
2025
Q1 		$18.4K Buy
549
+54
+11% +$2.02K ﹤0.01% 1546
2024
Q4 		$25.3K Sell
495
-66
-12% -$3.69K ﹤0.01% 1469
2024
Q3 		$28.7K Sell
561
-19
-3% -$980 ﹤0.01% 1399
2024
Q2 		$26K Sell
580
-3
-0.5% -$139 ﹤0.01% 1379
2024
Q1 		$27.3K Sell
583
-266
-31% -$10.4K ﹤0.01% 1365
2023
Q4 		$30.2K Sell
849
-19
-2% -$583 ﹤0.01% 1287
2023
Q3 		$25.8K Sell
868
-325
-27% -$6.7K ﹤0.01% 1272
2023
Q2 		$21.5K Buy
1,193
+344
+41% +$6.86K ﹤0.01% 1339
2023
Q1 		$13.6K Buy
+849
New +$15.7K ﹤0.01% 1446

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Huntington National Bank's CRNX Position: Q2 2026 in Review

Huntington National Bank reduced its Crinetics Pharmaceuticals (CRNX) stake by 4.9% in Q2 2026, selling an estimated $1.04K and leaving 545 shares worth $20.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1766.

Huntington National Bank first reported a position in CRNX in Q1 2023 and has held it in 14 quarters since. The position peaked at $30.2K in Q4 2023. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Huntington National Bank held 545 shares of Crinetics Pharmaceuticals worth $20.4K as of Q2 2026.
  • Huntington National Bank sold 28 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $1.04K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Huntington National Bank's portfolio in Q2 2026, its #1766 holding.
  • Huntington National Bank first reported a position in Crinetics Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • Huntington National Bank's Crinetics Pharmaceuticals position peaked at $30.2K in Q4 2023.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Huntington National Bank's 13F filing for Q2 2026, filed 13 Aug 2026.